Therefore, we infer that in the conventional-dose group, the higher recurrence rate of ROP in patients with a lower GA (the 25-28-week and 29-31-week subgroups) than in patients with a higher GA (the 32-34-week and 35-36-week subgroups) was likely because of the reincrease in VEGF concentration due to incomplete vascularization of the retina after ranibizumab metabolism in patients with a lower GA. This evidence concerns the gene VEGFA and retinopathy of prematurity.